8-KEarnings & ResultsExhibits & Filings

PFIZER INC 8-K Report, Financial Results (Jan 22, 2007)

Filed January 22, 2007For Securities:PFE

Summary

Pfizer Inc. (PFE) filed an 8-K report on January 22, 2007, to announce its fourth-quarter 2006 financial results. This filing primarily serves to incorporate by reference a press release detailing these results. Investors should note that the actual financial performance data, including revenue, earnings, and any forward-looking statements, are contained within the referenced press release, which is attached as Exhibit 99 to this filing. The 8-K itself does not provide the granular financial details but acts as the official notification mechanism to the SEC and the public. Investors seeking to understand Pfizer's performance in Q4 2006 will need to refer to the associated press release (Exhibit 99) for specific figures and commentary from management regarding the company's financial condition and operational results.

Key Highlights

  • 1Pfizer Inc. filed a Form 8-K on January 22, 2007.
  • 2The filing reports on the financial results for the fourth quarter of 2006.
  • 3The primary content of the report is a press release detailing these financial results.
  • 4The press release is incorporated by reference and attached as Exhibit 99.
  • 5The 8-K filing itself does not contain the detailed financial results, but directs investors to the press release.
  • 6This filing is a standard disclosure mechanism for significant financial events.

Frequently Asked Questions

The main purpose of this 8-K filing is to officially announce and incorporate by reference Pfizer Inc.'s press release containing its financial results for the fourth quarter of 2006. It serves as the SEC filing mechanism for this important financial disclosure.

The specific financial details, including revenue, earnings per share, and other key performance indicators for the fourth quarter of 2006, are located in the press release that is attached as Exhibit 99 to this 8-K filing. You will need to refer to that document for the actual numbers.

This 8-K filing itself does not contain new guidance. Any forward-looking statements, outlook, or management commentary regarding future performance would be included in the referenced press release (Exhibit 99).

When a document is 'incorporated herein by reference,' it means that for the purposes of SEC filings, the content of that document is considered part of the official filing. In this case, the press release is officially part of the 8-K report, and its contents are legally considered disclosed by Pfizer.